Director resigns; SEC concludes investigation with no enforcement action

Spero Therapeutics, Inc.

Ankit Mahadevia, MD resigned from board effective Jan 30, 2026 due to other professional commitments; no dispute with company.
Company intends to enter consulting agreement with Mahadevia for continued support.
SEC concluded its investigation on Jan 20, 2026; will not recommend enforcement action against company at this time.
Investigation was previously disclosed in SEC periodic reports.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.